Kornimate/medical-research-clean huggingface dataset:
phase i/ii nabpaclitaxel, paclitaxel&carboplatin w rtx followed by consolidation in patients w favorable prognosis inoperable stage iiia/b nsclc

Conditions: STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER

Summary: the investigators propose this phase i/ii study to use weekly nab-paclitaxel (abraxane) and carboplatin with concurrent radiation in local-regionally advanced lung cancer. there are no published human studies combining nab-paclitaxel (abraxane) with radiation. the investigators will first confirm the tolerated dose (td) of concurrent nab-paclitaxel (abraxane) at 50mg/m2, and then will begin enrolling patients into the phase ii component using either nab-paclitaxel (abraxane) at the td with carboplatin concurrent with daily radiation or paclitaxel with carboplatin concurrent with daily radiation.


Eligibility criteria:
inclusion criteria: * histologically or cytologically documented nsclc; patients must be m0. patients with t1-t2 with n2 or t3n1-2 are eligible, if inoperable. patients with t4 with any n or any t with n2 or n3 disease are eligible if unresectable. * patients with tumors adjacent to a vertebral body are eligible as long as all gross disease can be encompassed in the radiation boost field. the boost volume must be limited to \< 50% of the ipsilateral lung volume. * patients with zubrod performance status 0-1 * adequate hematologic function * fev1 with ≥ 1200 cc or ≥ 50% predicted exclusion criteria: * prior systemic chemotherapy (for lung cancer) and/or thoracic/neck radiotherapy for any reason and/or surgical resection of present cancer * exudative, bloody, or cytologically malignant effusions * prior therapy with any molecular targeted drugs (for lung cancer) * active pulmonary infection not responsive to conventional antibiotics * clinically significant cardiovascular event (e.g. myocardial infarction, superior vena cava syndrome (svc), new york heart association (nyha) classification of heart disease \>2 (see appendix b) within 3 months before entry; or presence of cardiac disease that, in the opinion of the investigator, increases the risk of ventricular arrhythmia. * patients with \> grade 1 neuropathy

Keywords: stage iiia/b nsclc / inoperable lung cancer
olanzapine versus an active comparator in the treatment of schizophrenia

Conditions: Schizophrenia

Summary: the purpose of this study is to determine how olanzapine compares to an active comparator in the treatment of schizophrenia


Eligibility criteria:
inclusion: 1. you must be between the ages of 18 and 75. if you have reached your 76th birthday, you will not be able to participate 2. you must have been diagnosed with schizophrenia 3. you must be able to visit the doctor's office as scheduled for the next 7 months exclusion: 1. you have a serious medical illness, such as heart, liver, or kidney disease (note: if you are uncertain about a particular condition, discuss it with your doctor.) 2. you are either pregnant or breastfeeding
selection of resistant mutations to dolutegravir in plwh treated in mozambique

Conditions: HIV; HIV Antiretroviral Therapy (ART) Adherence

Summary: the hiv infection not fully controlled, despite being under antiretroviral treatment, could make virus resistance against the antiretroviral treatments, making hardest the well control of hiv infection. the purpose of this research study is to confirm or deny if a not fully good controlled hiv infection could develop virus resistance against antiretroviral drugs that can difficult the good control of the hiv infection.

this research study consists of a single visit, in which you will be taken an additional vial of blood to analyze the presence or absence of mutations in your virus to hiv drugs. in addition, other hiv infection routine information will be recorded: * demographic data * hiv infection history data * virological failure information * laboratory parameters resistance tests techniques: genotyping resistance test will be performed from plasma samples in those patients with viral load over 200 copies/ml, using ultracentrifugation if needed (inzaule, seth c et al. j antimicrob chemother, 2018). briefly, rna will be extracted and hiv-1 pol gene will be amplified, followed by a nested-pcr. amplification products will be purified, quantified and finally diluted and prepared for sequencing following illumina dna sample preparation kit protocol (illumina, san diego, ca). samples will finally be pooled and sequenced in a miseq system (illumina). miseq sequences will be downloaded from basespace (illumina) and analysed using paseq (irsicaixa,barcelona,es), v1.4.18 (https://www.paseq.org). the questionnaire about clinical and demographic characteristics will be performed during the study visit

Eligibility criteria:
inclusion criteria: * patients able to understand and sign the informed consent form. * documented hiv-1 infection. * under the first line tld for at least 6 months. * at least 3 months follow-up with cv \&amp;gt;200c/ml. exclusion criteria: * patients \&amp;lt;18 years of age. * under the first line regime other than tld. * patients with active neoplastic processes. * patients with active opportunistic diseases. * patients unable to give informed consent.

Keywords: hiv arv resistance dtg africa
effect of passive smoking on platelet function and endothelial function

Conditions: Endothelial Function; Platelet Aggregation

Summary: passive smoking is associated with an increased risk for cardiovascular events. however, the exact mechanisms by which passive smoking affects cardiovascular health are not entirely understood. in the present study, the researchers investigate the effects of short-term exposure to secondhand smoke on platelet function and peripheral microvascular endothelial function in healthy individuals. for this purpose, platelet function and endothelial function are measured before and after a 1-hour exposure to secondhand smoke in a concentration that is encountered in bars and restaurants without smoke-free policies. the researchers' hypothesis is that short-term exposure leads to platelet activation and impairment of endothelial function.


Eligibility criteria:
inclusion criteria: * healthy individuals * nonsmokers * no regular medication (in particular no drugs affecting platelet function or vascular function) exclusion criteria: * exposition to secondhand smoke within 1 week before inclusion * use of drugs affecting platelet function or vascular function within 1 week before study inclusion

Keywords: secondhand smoke passive smoking platelet function endothelial function
phase 1/2 study to evaluate the safety, tolerability and pharmacokinetics of hqk-1001 administered daily in patients with sickle cell disease

Conditions: Sickle Cell Disease

Summary: the purpose of this study is to assess the safety and tolerability of hqk-1001 administered for a total of 12 weeks (with one dosing break) in subjects with sickle cell disease.


Eligibility criteria:
inclusion criteria: * diagnosis of scd or sickle beta thalassemia (excluding hemoglobin c) * between 12 and 60 years of age, inclusive * at least one episode of a scd-related crisis or complication (e.g., vaso-occlusive crisis, acute chest syndrome, priapism) per year for an average of 3 years or one episode of acute chest syndrome over the prior 5 years * screening (untransfused) hbf level \>/= 2% as analyzed by a central laboratory * if receiving hydroxyurea therapy, must be receiving a stable dose for at least 6 months * able and willing to give informed consent * if female, must have a negative serum pregnancy test within 7 days of dosing * if female, must not be of childbearing potential defined as post-menopausal by at least 2 years or surgically sterile, or must agree to use a medically accepted form of contraception throughout the study * if the sexual partner of a male subject is a wcbp, she must agree to use a medically accepted form of birth control for themselves or their partner throughout the study * in the view of the investigator, able to comply with necessary study procedures exclusion criteria: * red blood cell (rbc) transfusion within 3 months prior to beginning study medication * participation in a regular blood transfusion program * more than 4 hospitalizations for acute sickle cell-related events in the previous 12 months * an acute vaso-occlusive event within 3 weeks prior to receiving first dose of study medication * pulmonary hypertension requiring oxygen * qtc \> 450 msec on screening * alanine transaminase (alt) \> 3x upper limit of normal (uln) * creatinine phosphokinase (cpk) \> 20% above the uln * serum creatinine \>1.2 mg/dl * an acute illness (e.g., febrile, gastrointestinal \[gi\], respiratory) within 72 hours prior to receiving first dose of study medication * history of syncope, clinically significant dysrhythmias or resuscitation from sudden death * chronic opiate use which, in the view of the investigator, could confound evaluation of an investigational drug * current abuse of alcohol or drugs * received another investigational agent within 4 weeks, or 5 half-lives, whichever is longer, prior to administration of study medication * currently pregnant or breast feeding a child * known infection with hiv-1 * infection with hepatitis b or hepatitis c such that patients are currently on therapy or will be placed on therapy during the trial
therapeutic use of oral sodium phosphate (z-521) in primary hypophosphatemic rickets

Conditions: Primary Hypophosphatemic Rickets

Summary: the purpose of this study is to investigate the efficacy and safety of oral phosphate (z-521) in subjects with primary hypophosphatemic rickets.


Eligibility criteria:
inclusion criteria: * diagnosed as primary hypophosphatemic rickets based on familial history, genetic test or laboratory test results. exclusion criteria: * a hyperparathyroidism
the efficacy and safety of ibi-10090 for the treatment of inflammation associated with cataract surgery

Conditions: Inflammation; Cataracts

Summary: the purpose of this study is to determine whether ibi-10090 injection is effective in the treatment of inflammation associated with cataract surgery.

a double blinded randomized trial to assess the efficacy and safety of ibi-10090, in two separate doses as compared to placebo (atec carrier only sans dexamethasone)

Eligibility criteria:
inclusion criteria: 1. the patient must provide written informed consent by signing the informed consent approved by the institutional review board (irb). 2. male or female patients at least 40 years of age scheduled for unilateral cataract surgery by phacoemulsification with posterior chamber intraocular lens implantation. 3. the patient must demonstrate best corrected visual acuity (bcva) of 20/30-20/200 (with glare testing, if necessary) in the study eye and better than 20/200 in the fellow eye. 4. the patient must be considered by the investigator to have visual acuity potential greater than 20/30 in the study eye. 5. the patient must have a corneal endothelial cell count by specular microscopy in the study eye of at least 2000 cells/mm2 with normal cell morphology. 6. a female patient of childbearing potential (premenopausal by medical history) must have a negative pregnancy test on day 0 and be using an effective method of birth control (although no birth control method is 100% effective, the following are considered effective means of contraception: surgical sterilization, use of oral contraceptives, barrier contraception using either a condom or diaphragm with spermicidal gel, an intrauterine device, or contraceptive hormone implant or patch) from screening for the duration of the study. 7. the patient must be willing and able to understand and comply with the study procedures and to communicate meaningfully with study personnel. key exclusion criteria: 1. patients who have used any ocular, topical or oral corticosteroids within 7 days prior to day 0. 2. patients who have received a periocular corticosteroid injection in the study eye in the 3 months prior to screening. 3. patients who have received any intravitreal corticosteroid delivery vehicle (e.g., retisert, ozurdex, iluvien) in the study eye at any time. 4. patients who anticipate requiring treatment with any corticosteroids by any route, except inhalation, during the study. 5. patients with an allergy or hypersensitivity to dexamethasone. 6. patients who are known steroid responders (corticosteroid-related intraocular pressure elevation in either eye). 7. patients who have used topical ocular nsaids in the study eye within 15 days prior to day 0. 8. patients who have undergone prior intraocular (non-laser) surgery in the study eye within 6 months prior to screening. 9. patients who have undergone prior intraocular laser surgery in the study eye within 3 months prior to screening. 10. patients with planned intraocular or laser surgery in the study eye for the duration of the study.

Keywords: inflammation cataract surgery
clinical trial to evaluate the efficacy of ruti® against sars-cov-2 infection (covid-19) in healthcare workers

Conditions: Covid-19; Sars-CoV2

Summary: the purpose of this study is to assess the efficacy of ruti® vaccine preventing sars-cov-2 infection (covid-19) in healthcare workers.

the aim of this study is to assess the efficacy of ruti® vaccine preventing sars-cov-2 infection (covid-19) in healthcare workers. the study will include a comparison between placebo and ruti® vaccine.

Eligibility criteria:
inclusion criteria: 1. sign the informed consent before initiating the selection procedures. 2. healthcare system workers working in contact with subjects potentially infected with sars-cov-2. 3. people ≥ 18 years. 4. willingness to meet the requirements of the protocol. 5. negative rapid serological test of sars-cov-2 6. the participant must agree to use effective contraceptive methods during the study period, in case of childbearing age. exclusion criteria: 1. previous sars-cov-2 infection 2. pregnancy. pregnancy test will be performed in case of doubt. 3. breastfeeding. 4. suspected of active viral or bacterial infection. 5. symptoms compatible with covid-19, despite a negative polymerase chain reaction (pcr) test. 6. vaccination in the last 4 weeks or planned vaccination during the study period, except for influenza vaccine. 7. participation in a research that requires experimental intervention (does not include observational studies) in the previous month before signing the consent or during the study. 8. severely immunocompromised people. this exclusion category includes: 1. subjects with human immunodeficiency virus (hiv-1). 2. neutropenic subjects with less than 500 neutrophils / mm3. 3. subjects with solid organ transplantation. 4. subjects with bone marrow transplantation. 5. subjects undergoing chemotherapy. 6. subjects with primary immunodeficiency. 7. severe lymphopenia with less than 400 lymphocytes / mm3. 8. treatment with any anti-cytokine therapy. 9. oral treatment with steroids, defined as daily doses of 10 mg prednisone or equivalent for more than 3 months. 9. malignancy, or active solid or non-solid lymphoma from the previous two years. 10. bcg vaccination in the last 1year. 11. soy allergy. 12 chloroquine or hydroxychloroquine administration in the last two weeks. 13. direct involvement in the design or execution of the ruticovid19 clinical trial. 14 retirement, transfer, long-term leave (\> 1 month) due to scheduled surgery or any other event that makes it impossible to work in person at your health center during the months following the recruitment to the study. 15. employee at the health center \<22 hours per week. 16. do not have a smartphone. 17. detection by the researcher of lack of knowledge or willingness to participate and comply with all requirements of the protocol. 18. any other findings that, at the discretion of the researcher, may compromise compliance with the protocol or that may influence significantly the interpretation or the results of the effects of the vaccine.
self digital photography for assessing elbow range of motion

Conditions: Contracture of Elbow Joint

Summary: loss of elbow range of motion can significantly affect activities of daily living. measuring elbow range of motion is critical for tracking post surgical outcomes. this study seeks to validate the ability to validate self photography as a means of followup through long distance correspondence.

loss of elbow range of motion is common after trauma and can significantly affect activities of daily living. patients across the country travel to tertiary referral centers to have this problem addressed. followup is critical and can often be difficult given distances between patients home and their healthcare provider. measuring postoperative outcomes requires accurate and reliable documentation of range of motion. previously, the investigators have validated digital photography as a means of accurately measuring elbow range of motion. in that study, photographs were taken by a non-professional photographer. with the advance in personal technology, patients now have the ability to take photos themselves. this study seeks to validate self photography, which will ultimately improve patient follow up and improve clinical monitoring

Eligibility criteria:
inclusion criteria: * elbow contracture in the sagittal place exclusion criteria: * unable to read english * unable to forward flex shoulder to 90 degrees or hold their shoulder at 90 degrees for the duration of the examination * unable to tolerate the exercise due to pain
long time interval analysis for non invasive measurement of cardiac output

Conditions: Hypotension

Summary: a group of engineers at michigan state developed a novel waveform analysis technique ("long time interval analysis" \[ltia\]) that attempts to estimate cardiac output non-invasively. retrospective comparison of ltia to invasive techniques (e.g. thermodilution) suggest acceptable agreement. thus, a prospective trial of ltia is warranted. this study compares ltia to a validated measure of cardiac output - esophageal doppler monitoring.


Eligibility criteria:
inclusion criteria: * adult (18 years or older) * undergoing hepatobiliary surgery (open or laparoscopic) requiring general anesthesia as part of the patient's clinical care * attending anesthesiologist plans to place an intra-arterial catheter for routine care * attending anesthesiologist believes that non-invasive cardiac output monitoring would benefit the patient exclusion criteria: * minors (17 years or younger) * parturient (pregnant women) * cognitively impaired * unable to sign informed consent form * prisoner * prior esophageal surgery * moderate to severe aortic regurgitation * mechanical cardiac support (e.g., intra-aortic balloon pump) * severe, persistent arrhythmias
efficacy and safety study of fluvastatin and ezetimibe combined versus fluvastatin alone

Conditions: Dyslipidemia

Summary: the objective of this study is to assess the effect of the combination treatment on c-reactive protein and inflammatory markers as well as the safety and tolerability in a spanish population


Eligibility criteria:
inclusion criteria: * patients aged 18-75 primary hypercholesterolemia signed informed consent exclusion criteria: * patients involved in clinical trials 3 months prior to inclusion patients treated with drugs specified in protocol fertile women not using contraceptive methods other protocol defined in and exclusion criteria may apply

Keywords: dyslipidemia, ezetimibe, inflammatory markers, fluvastatin
study to assess clinical characteristics and outcome of patients with marginal zone lymphomas

Conditions: Marginal Zone B Cell Lymphoma

Summary: this is a purely retrospective and observational monocentric study

the study aimed at describing the characteristics and outcome of marginal zone lymphoma patients who were diagnosed and treated in our hospital between december 2012 and december 2018

Eligibility criteria:
inclusion criteria: 1. marginal zone lymphoma patients who were diagnosed and treated in our hospital between december 2012 and december 2018. 2. age ≥ 18 years at enrolment. 3. written informed consent (if applicable) exclusion criteria: * none
effectiveness of ketamine for depression and suicidal ideation in the emergency department

Conditions: Depression; Depression Severe; Depression Acute; Depression and Suicide; Suicidal Ideation

Summary: the purpose of this study is to examine the effect of a low-dose ketamine infusion on depression symptoms within the emergency department (ed) visit, and healthcare utilization after leaving the ed, when administered in the ed for depression or suicidal ideation.

patients will be identified based on either a chief complaint of suicidal ideation, suicide attempt, or severe depression, or if the patient indicates during intake assessment that they have thoughts of harming or killing their self. identified patients will be assessed by the ed provider for inclusion and exclusion criteria. if the patient is a candidate for the trial and gives their informed consent for enrollment, they will be randomized to receive either ketamine or placebo by a computer program that maintains blinding. the patient will be assessed by psychiatry for disposition and treatment plan prior to receiving the study drug, and will be reassessed four hours after the infusion. thirty days after the patient leaves the hospital (either leaves from the ed or is discharged from inpatient admission), they will be contacted to follow up on their healthcare utilization after discharge.

Eligibility criteria:
inclusion criteria: * adults 18 years of age and older * presenting to the ed with a chief complaint of severe depression or suicidality, or presenting to the ed with any other chief complaint but answering "yes" to "thoughts of harming/killing yourself?" during intake/triage exclusion criteria: * acute mania or psychosis * enrollment in trial during a prior emergency department visit * history of ketamine abuse or dependence * known hypersensitivity to ketamine * acute intoxication with any drug of abuse (including alcohol) * pregnancy or lactation * any condition that would place the patient at serious risk of harm from an increase in blood pressure (e.g. history of intracerebral hemorrhage, aneurysmal vascular disease, or arteriovenous malformation) * assessing provider does not want to enroll patient for any other reason, based on their clinical judgement

Keywords: ketamine depression suicidal ideation emergency department